CEO: Andrew Kay

Advent Contact: Shahzad Malik

Alpha-emitter anticancer agents

Algeta developed Xofigo® (radium-223 dichloride), a first-in-class, targeted alpha-pharmaceutical that was approved by the US FDA and European EMA for treatment of patients with symptomatic bone metastases secondary to castration-resistant prostate cancer.

Advent invested in the Series A in 2005. Algeta listed on the Oslo Stock exchange in March 2007 and was acquired by Bayer in 2014 for $2.9B.